Comparative Pharmacology
Head-to-head clinical analysis: IMKELDI versus MAVENCLAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMKELDI versus MAVENCLAD.
IMKELDI vs MAVENCLAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some AmpC enzymes.
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
10 mg orally once daily
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent